Tandospirone enhances the anti-myocardial fibrosis effect of valsartan in spontaneously hypertensive rats
Purpose: Myocardial fibrosis (MF) is an unavoidable complication in patients with hypertensive heart disease. Valsartan, a widely used antihypertensive drug, was reported to inhibit MF. Deficiency in the 5-hydroxytryptamine (5-HT, serotonin) transporter gene has been proven to cause MF. Long-term sy...
Main Authors: | Xuefei Huang, Yaqi Kang, Xinrui Jiang, Jing Yang, An-Guo Wu, Chuanqing Zhang, Dalian Qin, Shousong Cao, Qibin Mei, Yun Ye, Jianming Wu |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-06-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S075333222030264X |
Similar Items
-
5-HT1A receptor agonists, xaliproden and tandospirone, inhibit the increase in the number of cutaneous mast cells involved in the exacerbation of mechanical allodynia in oxaliplatin-treated mice
by: Tsugunobu Andoh, et al.
Published: (2016-08-01) -
Protective Effects of Sacubitril/Valsartan on Cardiac Fibrosis and Function in Rats With Experimental Myocardial Infarction Involves Inhibition of Collagen Synthesis by Myocardial Fibroblasts Through Downregulating TGF-β1/Smads Pathway
by: Meifang Wu, et al.
Published: (2021-05-01) -
The Role of the TGF-β Superfamily in Myocardial Infarction
by: Anis Hanna, et al.
Published: (2019-09-01) -
The impact of dose of the angiotensin-receptor blocker valsartan on the post-myocardial infarction ventricular remodeling: study protocol for a randomized controlled trial
by: Cho Young-Rak, et al.
Published: (2011-11-01) -
Mir-21 Promotes Cardiac Fibrosis After Myocardial Infarction Via Targeting Smad7
by: Jinxia Yuan, et al.
Published: (2017-08-01)